Veradermics MANE
NYSE MANE
$117.54 +2.54 (+2.21%)
As of: Sep 29, 2026 · 3:59 PM EDT

Veradermics (MANE) Enterprise Value (2026)

Updated

Veradermics' Enterprise Value was $4.32 billion in Q2 2026, up 313.9% from the prior quarter.

Analysis

Veradermics (MANE) Enterprise Value (2026) Analysis & Trends

On a trailing twelve-month basis, Veradermics' Enterprise Value was $3.73 billion through Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Veradermics 4.80 Bn 4.80 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.32 Bn
Mar 31, 2026 1.04 Bn
API Access

Veradermics Enterprise Value API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=enterprise-value&ticker=MANE&period=max&api_key=YOUR_API_KEY